Literature DB >> 37871

Effect of beta-blockers on exercise double product (systolic blood pressure x heart rate).

R A Vukovich, J E Foley, B Brown, D A Willard, M Buckley, D O'Kelly, D Fitzgerald, W Tormey, A Darragh.   

Abstract

1 The effect of single oral doses of six beta-receptor antagonists on exercise-induced changes in double product (systolic blood pressure x heart rate) were studied in 25 human volunteers. 2 Three doses of propranolol, nadolol, oxprenolol, pindolol, timolol and atenolol were selected for study on the basis of in vivo beta-blocking potency. 3 Although all beta-blockers studied reduced the double product response to exercise, the pharmacodynamics of this effect differed markedly. 4 Pharmacodynamic half-lives, estimated for the drug tested, were 39 h for nadolol, atenolol 21 h, timolol 15 h, oxprenolol 13 h, propranolol 11 and pindolol 8 h. 5 These results suggest that the clinical choice of a beta-blocker with the least problems of compliance can be made on the basis of pharmacodynamics as well as pharmacological profile.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 37871      PMCID: PMC1429319          DOI: 10.1111/j.1365-2125.1979.tb04687.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Plasma concentrations and the time-course of beta blockade due to propranolol.

Authors:  D G McDevitt; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-12       Impact factor: 6.875

Review 2.  The clinical pharmacology of beta-adrenoceptor-blocking drugs.

Authors:  M E Conolly; F Kersting; C T Dollery
Journal:  Prog Cardiovasc Dis       Date:  1976 Nov-Dec       Impact factor: 8.194

Review 3.  Angina pectoris: getting the most from drug therapy.

Authors:  H B Kay
Journal:  Drugs       Date:  1977-04       Impact factor: 9.546

Review 4.  Metoprolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1977-11       Impact factor: 9.546

5.  Clinical pharmacokinetics of atenolol.

Authors:  J McAinsh
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

6.  Effect of propranolol on myocardial oxygen consumption and its hemodynamic correlates during upright exercise.

Authors:  C R Jorgensen; K Wang; Y Wang; F L Gobel; R R Nelson; H Taylor
Journal:  Circulation       Date:  1973-12       Impact factor: 29.690

7.  Hemodynamic correlates of myocardial oxygen consumption during upright exercise.

Authors:  K Kitamura; C R Jorgensen; F L Gobel; H L Taylor; Y Wang
Journal:  J Appl Physiol       Date:  1972-04       Impact factor: 3.531

Review 8.  Inhibition of the adrenergic nervous system in the treatment of angina pectoris.

Authors:  S E Epstein; E Braunwald
Journal:  Med Clin North Am       Date:  1968-09       Impact factor: 5.456

Review 9.  The pharmacology of beta-adrenergic blocking agents.

Authors:  B R Lucchesi; L S Whitsitt
Journal:  Prog Cardiovasc Dis       Date:  1969-03       Impact factor: 8.194

10.  Beta adrenergic blockade. Hemodynamics and myocardial energy metabolism in patients with ischemic heart disease.

Authors:  C M Lewis; A J Brink
Journal:  Am J Cardiol       Date:  1968-06       Impact factor: 2.778

  10 in total
  10 in total

1.  Comparison of single-dose and steady-state nadolol plasma concentrations.

Authors:  J J Krukemyer; H Boudoulas; P F Binkley; J J Lima
Journal:  Pharm Res       Date:  1990-09       Impact factor: 4.200

2.  Bioequivalence of a highly variable drug: an experience with nadolol.

Authors:  R G Buice; V S Subramanian; K L Duchin; S Uko-Nne
Journal:  Pharm Res       Date:  1996-07       Impact factor: 4.200

3.  Pharmacokinetic-pharmacodynamic modelling of oxprenolol in man using continuous non-invasive blood pressure monitoring.

Authors:  R Koopmans; B Oosterhuis; J M Karemaker; J Wemer; C J van Boxtel
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Receptor binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man.

Authors:  A Wellstein; D Palm; H F Pitschner; G G Belz
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Comparison between atenolol and nadolol in essential hypertension at rest and on exercise.

Authors:  R G Wilcox; J R Hampton
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

6.  Comparison of antianginal efficacy of one conventional and three long acting beta-adrenoreceptor blocking agents in stable angina pectoris.

Authors:  G R Jones; M A Mir
Journal:  Br Heart J       Date:  1981-11

7.  Concentration-effect and time-effect relationships of carteolol.

Authors:  T Ishizaki; A Ohnishi; T Sasaki; K Chiba; T Suganuma; K Kushida
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 8.  Nadolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris.

Authors:  R C Heel; R N Brogden; G E Pakes; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-07       Impact factor: 9.546

9.  Effect of a long acting beta-adrenoceptor blocker on diurnal variation of cardiac dysrhythmias.

Authors:  M A Mir
Journal:  Postgrad Med J       Date:  1986-03       Impact factor: 2.401

10.  Electrophysiological abnormalities and enhanced reperfusion arrhythmias in the isolated hearts of hyperthyroid rats.

Authors:  K Miyazawa; H Hashimoto; T Uematsu; M Nakashima
Journal:  Br J Pharmacol       Date:  1989-08       Impact factor: 8.739

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.